CoChat
Sign Up
Cited by 286TGF-β signaling in diseasesNitric Oxide and Endothelin EffectsCancer Cells and Metastasis

The DOI matches its Crossref record; 120 of the 123 references it cites were found in a registry or an index.

Endothelial to Mesenchymal Transition Represents a Key Link in the Interaction between Inflammation and Endothelial Dysfunction

Open access
Cho, Jin Gu, Lee, Aram, Chang, Woochul, Lee, Myeong-Sok, Kim, Jongmin·2018·Frontiers in Immunology
DOI 10.3389/fimmu.2018.00294PMC PMC5826197
Open this paper in CoChat — free accountOpen PDF

Abstract

Endothelial cells that line the inner walls of blood vessels are in direct contact with blood and display remarkable heterogeneity in their response to exogenous stimuli. These endothelial cells have unique location-dependent properties determined by the corresponding vascular beds and play an important role in regulating the homeostasis of the vascular system. Evidence suggests that vascular endothelial cells exposed to various environments undergo dynamic phenotypic switching, a key biological program in the context of endothelial heterogeneity, but that might result in endothelial cell dysfunction and, in turn, cause a variety of human diseases. Emerging studies show the importance of endothelial to mesenchymal transition (EndMT) in endothelial dysfunction during inflammation. EndMT is a complex biological process in which endothelial cells lose their endothelial characteristics, acquire mesenchymal phenotypes, and express mesenchymal cell markers such as alpha smooth muscle actin and fibroblast specific protein 1. EndMT is induced by inflammatory responses, leading to pathological states, including tissue fibrosis, pulmonary arterial hypertension, and atherosclerosis, via dysfunction of the vascular system. Although the mechanisms associated with inflammation-induced EndMT have been identified, unraveling the specific role of this phenotypic switching in vascular dysfunction remains a challenge. Here, we review the current understanding on the interactions between inflammatory processes, EndMT, and endothelial dysfunction, with a focus on the mechanisms that regulate essential signaling pathways. Identification of such mechanisms will guide future research and could provide novel therapeutic targets for the treatment of vascular diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2018.00294

Cites

120 of 120 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Schematic representation of endothelial to mesenchymal transition (EndMT) transition in response to inflammatory stimuli and metabolic dysfunction. Upon chronic inflammatory conditions, involving tumor necrosis factor-α (TNF-α), transforming growth factor beta (TGFβ), IL-1β, and endotoxin and metabolic dysfunction, such as increased serum LDL, glucose, diverse ECs undergo activation, which results in loss of endothelial cell markers and acquisition of mesenchymal-cell markers. EndMT contributes to endothelial dysfunction under inflammatory conditions and metabolic dysfunction, with EndMT mediators identified. This process can cause a variety of postnatal diseases, such as fibrosis, PAH, and metabolic syndrome.
Figure 1 Schematic representation of endothelial to mesenchymal transition (EndMT) transition in response to inflammatory stimuli and metabolic dysfunction. Upon chronic inflammatory conditions, involving tumor necrosis factor-α (TNF-α), transforming growth factor beta (TGFβ), IL-1β, and endotoxin and metabolic dysfunction, such as increased serum LDL, glucose, diverse ECs undergo activation, which results in loss of endothelial cell markers and acquisition of mesenchymal-cell markers. EndMT contributes to endothelial dysfunction under inflammatory conditions and metabolic dysfunction, with EndMT mediators identified. This process can cause a variety of postnatal diseases, such as fibrosis, PAH, and metabolic syndrome.CC BY · PubMed Central
Figure 2 A schematic illustration of the signaling pathways governing endothelial to mesenchymal transition (EndMT). Tumor necrosis factor-α (TNF-α), transforming growth factor beta (TGFβ), interleukin (IL)-1β, and high glucose influences EndMT by regulating signaling pathways. These pathways converge and induce the expression of transcription factors involving Slug, Snail and zinc finger E-box-binding homeobox 1 (ZEB1) (see text for details).
Figure 2 A schematic illustration of the signaling pathways governing endothelial to mesenchymal transition (EndMT). Tumor necrosis factor-α (TNF-α), transforming growth factor beta (TGFβ), interleukin (IL)-1β, and high glucose influences EndMT by regulating signaling pathways. These pathways converge and induce the expression of transcription factors involving Slug, Snail and zinc finger E-box-binding homeobox 1 (ZEB1) (see text for details).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 123 references

Cited by

Sorted by citations

See all 286

Related

Metadata

Authors
Cho, J. G., Lee, A., Chang, W., Lee, M.-S., & Kim, J.
Affiliations
  • Sookmyung Women's University (KR)
  • Pusan National University (KR)
Corresponding author
Kim, Jongmin
ORCID
Venue
Frontiers in Immunology
Publisher
Frontiers Media SA
Published
2018-02-20
Volume
9
Pages
294-294
ISSN
1664-3224 (ISSN-L)
DOI
10.3389/fimmu.2018.00294
PMC
PMC5826197
OpenAlex
W2793749910
Cited by
284
References
123
Citations by year
2026: 25 · 2025: 38 · 2024: 33 · 2023: 40 · 2022: 29 · 2021: 36 · 2020: 49 · 2019: 26 · 2018: 7
FWCI
2.89
Type
journal article
Language
en
Open access
Licence
Locations
  • Frontiers in Immunology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Research Foundation (NRF-2016R1A5A1011974)
  • National Research Foundation of Korea (NRF-2016R1A5A1011974, NRF-2016R1C1B2006591, 2016R1A5A1011974)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
  • Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords
endothelial-to-mesenchymal transition, endothelial dysfunction, inflammation, endothelial heterogeneity, fibrosis, pulmonary arterial hypertension, atherosclerosis, vascular dysfunction, signaling pathways, therapeutic target
MeSH terms
Humans, Inflammation, Vascular Diseases, Endothelial Cells, Cell Transdifferentiation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review